These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30680510)

  • 1. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
    Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
    J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Franceschi E; Lamberti G; Paccapelo A; Di Battista M; Genestreti G; Minichillo S; Mura A; Bartolini S; Agati R; Brandes AA
    J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.
    Choi SW; Shin H; Sa JK; Cho HJ; Koo H; Kong DS; Seol HJ; Nam DH
    Cancer Med; 2018 May; 7(5):1774-1783. PubMed ID: 29573206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
    Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
    Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.
    Urup T; Gillberg L; Kaastrup K; Lü MJS; Michaelsen SR; Andrée Larsen V; Christensen IJ; Broholm H; Lassen U; Grønbaek K; Poulsen HS
    Mol Oncol; 2020 May; 14(5):964-973. PubMed ID: 32133779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
    Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
    Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
    Shen CC; Cheng WY; Lee CH; Dai XJ; Chiao MT; Liang YJ; Hsieh WY; Mao TF; Lin GS; Chen SR; Liu BS; Chen JP
    BMC Cancer; 2020 Jul; 20(1):709. PubMed ID: 32727419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma.
    Hiller-Vallina S; Mondejar-Ruescas L; Caamaño-Moreno M; Cómitre-Mariano B; Alcivar-López D; Sepulveda JM; Hernández-Laín A; Pérez-Núñez Á; Segura-Collar B; Gargini R
    Neuro Oncol; 2024 Jul; 26(7):1213-1227. PubMed ID: 38411438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
    Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
    J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
    Toh CH; Liau CT; Wei KC; Castillo M
    J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
    Auer TA; Renovanz M; Marini F; Brockmann MA; Tanyildizi Y
    J Neurooncol; 2017 Jul; 133(3):571-579. PubMed ID: 28555422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
    J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
    Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
    Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
    Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
    J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma.
    Fu M; Hussain A; Dong Y; Fei Y
    J Clin Neurosci; 2021 Apr; 86():110-115. PubMed ID: 33775313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy.
    Bronnimann C; Izquierdo C; Cartalat S; Thomas L; Joubert B; Delpech L; Barritault M; Meyronet D; Honnorat J; Ducray F
    J Neurooncol; 2018 May; 138(1):141-145. PubMed ID: 29388033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
    Sinkó D; Nemeskéri C
    Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.
    Quillien V; Carpentier AF; Gey A; Avril T; Tartour E; Sejalon F; Campillo-Gimenez B; Vauleon E
    Cancer Immunol Immunother; 2019 Jun; 68(6):871-882. PubMed ID: 30830269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.